MiMedx Group Inc (MDXG) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (83% profit margin, 47% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-01, MiMedx Group Inc (NASDAQ: MDXG) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $3.97 (+0.51% 1D, market cap $579.3M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, MDXG ranks #30 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), MDXG carries a Roarable B+ (77/100 RQD), trailing P/E of 11.9x, gross margin of 82.6%, and ROIC of 47.2%. By comparison, TCMD (Tactile Systems Technology Inc.) holds a B+ grade (78/100 RQD, P/E 28.9x, ROIC 17.1%, cap $550.7M) and SGHT (Sight Sciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $527.2M). Among the 5-stock peer group, MDXG leads on earnings multiple (11.9x) while MDXG leads on capital efficiency (47.2% ROIC).
Per MDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001376339), MiMedx Group Inc generated $418.6M in revenue (+20.0% YoY), $48.6M in net income, and $74.0M in free cash flow against $342.7M in total assets and $16.5M in total debt. Key quantitative strengths: Strong cash generator (83% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
SEC XBRL FY 2025 (10-K): 17.7% FCF Margin ($74.0M FCF) & 82.6% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
Even with a 77/100 (B+) score, MDXG faces multiple-compression risk if 11.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 80.1% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.49) or 200D SMA ($4.27) invalidates the momentum regime and cuts Target Base ($4.31) toward Bear Floor ($3.26).
MiMedx Group Inc (MDXG) advanced +0.51% to $3.97, trading at 19% of its 52-week range ($3.03 – $7.97). High-quality cash engine (83% profit margin, 47% return on capital) with steady institutional support.
MiMedx Group came into this Q3 2026 report under a simple thesis in many investors minds. A low P/S multiple and growth forecasts were meant to offset real concerns about ongoing losses. Then the numbers hit. The stock s
Moby summary of MiMedx Group, Inc.'s Q3 2026 earnings call
Surgical revenue grew 9% despite 45% net sales decline from Medicare changes.
MiMedx Group (NASDAQ:MDXG) reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical
(MDXG) on Wednesday reported a loss of $8.The Marietta, Georgia-based company said it had a loss of 6 cents per share.
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL® Regula
MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves alleg
MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDTCompany ParticipantsMatthew Notarianni - Head of Investor RelationsJoseph Capper...
MiMedx Group (NASDAQ:MDXG) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6 billion. As
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MDXG today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MDXG. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, MiMedx Group Inc (MDXG) ranks #30 by composite RQD confidence (77/100, grade B+) and #426 by equity capitalization ($579.3M). Within this direct 5-issuer industry benchmark cohort, MDXG leads on earnings valuation at 11.9x trailing P/E, while MDXG leads on capital efficiency and profitability with 47.2% ROIC and 82.6% gross margin. TCMD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with MDXG at 77/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MDXG
ACTIVE
MiMedx Group Inc | B+ | 77/100 | 11.9x | 82.6% | 47.2% | +0.51% | $579.3M | Benchmark Subject |
| TCMD Tactile Systems Technology Inc. | B+ | 78/100 | 28.9x | 75.9% | 17.1% | +1.67% | $550.7M | /tcmd-vs-mdxg → |
| SGHT Sight Sciences Inc. | D- | 38/100 | — | 86.2% | -35.0% | +3.57% | $527.2M | /sght-vs-mdxg → |
| ANGO AngioDynamics Inc. | D | 50/100 | — | 54.6% | -23.4% | +1.81% | $519.4M | /ango-vs-mdxg → |
| RCEL Avita Medical Inc. | D | 44/100 | — | 82.1% | -35.0% | +1.27% | $516.8M | /rcel-vs-mdxg → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), MiMedx Group Inc (MDXG) reported GAAP revenue of $418.6M (+20.0% vs. FY2024 revenue of $348.9M , and +30.2% cumulative change since FY2023) , GAAP net income of $48.6M, operating cash flow of $74.0M, and free cash flow of $74.0M (+11.8% YoY). On the balance sheet, MDXG closed FY2025 with $342.7M in total assets against $16.5M in total debt (Altman Z-Score: 6.45, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $418.6M | $48.6M | $74.0M | $74.0M | $342.7M | $16.5M |
| FY2024 (FY) | 2024-12-31 | $348.9M | $42.4M | $66.2M | $66.2M | $263.9M | $17.8M |
| FY2023 (FY) | 2023-12-31 | $321.5M | $58.2M | $26.8M | $26.8M | — | — |
As of 2026-11-01, MiMedx Group Inc (NASDAQ: MDXG) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $3.97 (+0.51% 1D, market cap $579.3M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, MDXG ranks #30 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), MDXG carries a Roarable B+ (77/100 RQD), trailing P/E of 11.9x, gross margin of 82.6%, and ROIC of 47.2%. By comparison, TCMD (Tactile Systems Technology Inc.) holds a B+ grade (78/100 RQD, P/E 28.9x, ROIC 17.1%, cap $550.7M) and SGHT (Sight Sciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $527.2M). Among the 5-stock peer group, MDXG leads on earnings multiple (11.9x) while MDXG leads on capital efficiency (47.2% ROIC).
Per MDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001376339), MiMedx Group Inc generated $418.6M in revenue (+20.0% YoY), $48.6M in net income, and $74.0M in free cash flow against $342.7M in total assets and $16.5M in total debt. Key quantitative strengths: Strong cash generator (83% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
MDXG last traded at $3.97 (+0.51% on volume of 4,044,148 shares), positioning the stock -11.58% below its 50-day simple moving average ($4.49) and -7.03% below its 200-day simple moving average ($4.27). Across its 52-week range of $3.03 to $7.97, MDXG sits at the 19.0% percentile with a 14-day RSI of 32.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($3.55 to $4.39).
Why MDXG Stock advanced +0.51% Today — RQD Quant Desk Flash. High-quality cash engine (83% profit margin, 47% return on capital) with steady institutional support.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.